SCHEMBL2339713

SCHEMBL2339713

COc1cc(CN(CCC(C)O)S(=O)(=O)c2ccc(Cl)cc2)ccc1OCCc1scnc1C

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
HTT P42858 2/20 0.40
THRB P10828 1/20 0.40
HIF1A Q16665 1/20 0.40
EPAS1 Q99814 1/20 0.40
ALDH1A1 P00352 7/20 0.39
TAS2R14 Q9NYV8 2/20 0.39
BDKRB1 P46663 1/20 0.39
TSHR P16473 2/20 0.38
MAPT P10636 1/20 0.38
PTGER1 P34995 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2333362 0.94 HIF1A (0.46) MEN1KMT2ALMNASMN1; SMN2HTT
SCHEMBL2338098 0.92 ALDH1A1 (0.40) MEN1KMT2ALMNASMN1; SMN2HTT
SCHEMBL5668449 0.92 MEN1 (0.40) MEN1KMT2ALMNASMN1; SMN2HTT
SCHEMBL2338966 0.90 MEN1 (0.42) MEN1KMT2ALMNASMN1; SMN2HTT
SCHEMBL2339348 0.88 ALDH1A1 (0.43) MEN1KMT2ALMNASMN1; SMN2HTT
SCHEMBL2332022 0.88 ALDH1A1 (0.39) MEN1KMT2ALMNASMN1; SMN2HTT
SCHEMBL2332987 0.88 MEN1 (0.41) MEN1KMT2ALMNASMN1; SMN2HTT
SCHEMBL2334778 0.87 LMNA (0.41) MEN1KMT2ALMNASMN1; SMN2HTT
SCHEMBL2337909 0.86 ALDH1A1 (0.44) MEN1KMT2ALMNASMN1; SMN2HTT
SCHEMBL2332019 0.85 HIF1A (0.45) MEN1KMT2ALMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US claimed
EP-2360142-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-08-24 EP claimed
EP-1723102-A2 N-SUBSTITUTED BENZENE SULFONAMIDES Elan Pharmaceuticals, Inc. (US) 2006-11-22 EP claimed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US claimed
WO-2005090296-A2 N-SUBSTITUTED BENZENE SULFONAMIDES ELAN PHARMACEUTICALS, INC. (US) 2005-09-29 WO claimed
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US disclosed
US-8193389-B2 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-06-05 US disclosed
EP-2374792-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-10-12 EP disclosed
EP-2360142-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-08-24 EP disclosed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245573-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE MEN1 2523/4885KMT2A 1360/4885LMNA 3051/4885
US-20120270902-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE MEN1 2523/4885KMT2A 1360/4885LMNA 3051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.